In Brief: Rhone-Poulenc Rorer Lovenox
Executive Summary
Rhone-Poulenc Rorer Lovenox: FDA's Cardiovascular & Renal Drugs Advisory Committee will review Lovenox (enoxaparin) injection (NDA 20-614) with aspirin for the treatment of unstable angina and non-Q-wave myocardial infarction at its June 26 meeting. Neurex' Corlopam (NDA 19-922) will also be reviewed at the meeting ("The Pink Sheet" April 21, In Brief). The meeting will be held at the National Institute of Health's Masur Auditorium in Bethesda, Md., starting at 9 a.m...